PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara Grazia Chisari, Francesco Corea, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 15
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7